July 2014 By Polly Clayden Since last year’s Pipeline Report, dolutegravir (DTG) was approved for children aged 12 years and older in the United States and Europe.1,2 The approvals for this age group were granted at the same time as…
July 2014 By Polly Clayden Since the 2013 Pipeline Report treatment optimization has continued to gain traction. Results from one of the key dose optimization trials ENCORE1—showing a lower dose of efavirenz (EFV) is non-inferior to the currently approved one—…
Update July 18, 2014 Disappointing news regarding the "Mississippi baby" case described in this chapter was announced on July 10th by the National Institute of Allergy and Infectious Diseases (NIAID). Viral load rebounded to detectable levels, dashing hopes that a…
July 2014 By Tim Horn and Richard Jefferys The U.S. Food and Drug Administration (FDA) approval of co-formulated tenofovir DF and emtricitabine (Truvada) as preexposure prophylaxis (PrEP) has transformed the HIV prevention landscape, though perhaps more in theory than reality.…
July 2014 By Tim Horn and Simon Collins Introduction By 2024, antiretroviral treatment (ART) could be as different from that used today as triple therapy in 1997 was from AZT monotherapy in 1987, or as dramatically evolved as the once-daily…
July 2015 By Richard Jefferys Introduction The rise to prominence of cure research has continued over the past year, with every major scientific conference on HIV now featuring sessions and presentations on the topic. The U.S. National Institute of Allergy…
July 2015 By Tim Horn and Richard Jefferys Though global HIV incidence has declined by an estimated 33% since 2001, more than 2 million people continue to be infected with the virus every year – approximately 6,000 new infections every…
July 2015 By Polly Clayden Introduction The big news since the 2014 Pipeline Report is that there is finally a solid form of lopinavir/ritonavir (LPV/r) suitable for infants and young children. On 21 May 2015, the United States Food and…
July 2015 By Polly Clayden The most striking news since the 2014 Pipeline Report is from the START (Strategic Timing of AntiRetroviral Treatment) study.1 We now have evidence from a large, randomized, controlled trial to show that CD4 count is…
July 2015 By Simon Collins and Tim Horn INTRODUCTION As a global community of people living with HIV, our needs from the antiretroviral (ARV) pipeline have changed considerably over the last 20 years. Antiretroviral treatment (ART), particularly for people starting treatment,…